Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Top Cited Papers
- 20 August 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (24) , 3621-3627
- https://doi.org/10.1200/jco.2006.10.2517
Abstract
Purpose Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity of study population. The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC. Patients and Methods A retrospective review of demographic, pathologic, treatment, and outcome data from 1,895 patients with International Federation of Gynecology and Obstetrics stage III EOC who had undergone primary surgery followed by six cycles of intravenous platinum/paclitaxel was conducted. A proportional hazards model was used to assess the association of prognostic factors with progression-free survival (PFS) and overall survival (OS). Results Increasing age was associated with increased risks for disease progression (HR = 1.06; 95% CI, 1.02 to 1.11 for an increase every 10 years) and death (HR = 1.12; 95% CI, 1.06 to 1.18). Mucinous or clear-cell histology was associated with a...Keywords
This publication has 35 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Identification of Prognostic Factors in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective StudyGynecologic Oncology, 2001
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Epithelial ovarian carcinoma in the reproductive age groupCancer, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1994
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991
- Aggressive chemosurgical debulking in patients with advanced ovarian cancerGynecologic Oncology, 1990